+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
FEMALE
ID07543536

Evaluating Megestrol Acetate Plus Trastuzumab Deruxtecan for Fatigue in Advanced Breast Cancer Patients

Led by Sun Yat-sen University · Updated on 2026-08-14

132

Participants Needed

2

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether adding Megestrol Acetate at the start of Trastuzumab Deruxtecan T-DXd treatment can help reduce fatigue in women with advanced breast cancer. This trial focuses on patients with HER2-positive, HER2-low, or HER2-ultralow advanced or metastatic breast cancer who have not previously received T-DXd. The study aims to improve quality of life by evaluating fatigue levels and safety of this combination treatment. Participants will be randomly assigned to receive either Megestrol Acetate alongside standard T-DXd therapy or a placebo with standard T-DXd. Megestrol Acetate is given orally at 160 mg on days 1 to 5 every three weeks for two cycles, while T-DXd is administered as a 5.4 mgkg intravenous infusion every three weeks. The study is double-blind and includes two treatment cycles, each lasting 28 days. During the trial, participants will be closely monitored with assessments of fatigue using the FACIT-Fatigue Scale and Brief Fatigue Inventory at multiple time points. Other evaluations include tumor response rates, patient-reported outcomes, and safety checks from the first dose until 30 days after treatment ends. The primary fatigue measurement is taken from baseline to approximately six weeks. Overall participation may last several months, with regular visits for treatment and assessments to track effects and safety.

CONDITIONS

Brief Title

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Research Team

M

Meiting Chen Doctor, PhD / Doctorate

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here